Core Viewpoint - Meihua Medical (301363) has shown a mixed financial performance with a slight increase in revenue but a significant decline in net profit for the first three quarters of 2025 [2] Financial Performance - For the first three quarters of 2025, Meihua Medical reported a main revenue of 1.194 billion yuan, an increase of 3.28% year-on-year [2] - The net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% year-on-year [2] - The net profit excluding non-recurring items was 203 million yuan, down 17.85% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year [2] - The single-quarter net profit attributable to shareholders was 93.9 million yuan, an increase of 5.89% year-on-year [2] - The single-quarter net profit excluding non-recurring items was 92.7 million yuan, up 9.56% year-on-year [2] - The company's debt ratio stands at 11.43% with investment income of 4.9031 million yuan and financial expenses of -27.391 million yuan [2] - The gross profit margin is reported at 39.34% [2] Market Activity - As of February 12, 2026, Meihua Medical's stock closed at 32.73 yuan, up 2.35% with a turnover rate of 2.83% [1] - The trading volume was 105,500 hands, with a total transaction amount of 343 million yuan [1] - On February 12, the net inflow of main funds was 4.0265 million yuan, accounting for 1.17% of the total transaction amount [1] - The net inflow of speculative funds was 16.4967 million yuan, representing 4.81% of the total transaction amount [1] - Retail investors experienced a net outflow of 20.5232 million yuan, which is 5.99% of the total transaction amount [1] Analyst Ratings - In the last 90 days, five institutions have given buy ratings for Meihua Medical, with an average target price of 2.457 billion yuan [3]
股票行情快报：美好医疗（301363）2月12日主力资金净买入402.65万元